Ascendis Pharma A/S expected to post a loss of €2.56 a share - Earnings Preview

Ascendis Pharma A/S

14/02/2023 11:28

* Ascendis Pharma A/S  ASND.OQ   ASND.O  is expected to show
a
rise in quarterly revenue when it reports  results on February
16. 
    * The Hellerup Denmark-based   company is expected to report
 a
305.1% increase in revenue to €19.836 million from €4.9 million
a year ago, according to the mean estimate from 10 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Ascendis Pharma A/S
is
for a loss of €2.56 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Ascendis
Pharma
A/S is $161.5​, above​ its last closing price of $113.89. ​​​

Previous quarterly performance (using preferred earnings measure
in euros). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -2.49       -2.49      -3.03     Missed  -21.7
 Jun. 30 2022  -2.08       -2.13      -1.46     Beat    31.5
 Mar. 31 2022  -1.98       -2.00      -2.21     Missed  -10.5​
 Dec. 31 2021  -2.39       -2.34      -1.87     Beat    20.2
 ​​Sep.        -2.30       -2.29      -1.47     Beat    35.9
 30 2021                                                
 Jun. 30 2021  -2.22       -2.23      -2.50     Missed  -12.3​
 Mar. 31 2021  -1.70       -1.71      -1.17     Beat    31.4
 Dec. 31 2020  -1.59       -1.55      -2.64     Missed  -70.3
 This summary was machine generated February 14 at 11:28 GMT. 
All figures in euros  unless otherwise stated